197 related articles for article (PubMed ID: 1413839)
1. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract.
Schürmann G; Raeth U; Wiedenmann B; Buhr H; Herfarth C
World J Surg; 1992; 16(4):697-701; discussion 701-2. PubMed ID: 1413839
[TBL] [Abstract][Full Text] [Related]
2. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
3. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience.
Stivanello M; Berruti A; Torta M; Termine A; Tampellini M; Gorzegno G; Angeli A; Dogliotti L
Ann Oncol; 2001; 12 Suppl 2():S73-7. PubMed ID: 11762356
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A: its clinical value as marker of neuroendocrine tumours.
Nobels FR; Kwekkeboom DJ; Bouillon R; Lamberts SW
Eur J Clin Invest; 1998 Jun; 28(6):431-40. PubMed ID: 9693933
[TBL] [Abstract][Full Text] [Related]
5. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
Baudin E; Gigliotti A; Ducreux M; Ropers J; Comoy E; Sabourin JC; Bidart JM; Cailleux AF; Bonacci R; Ruffié P; Schlumberger M
Br J Cancer; 1998 Oct; 78(8):1102-7. PubMed ID: 9792158
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm.
Wang YH; Yang QC; Lin Y; Xue L; Chen MH; Chen J
Medicine (Baltimore); 2014 Dec; 93(27):e247. PubMed ID: 25501094
[TBL] [Abstract][Full Text] [Related]
7. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours.
Bernini GP; Moretti A; Ferdeghini M; Ricci S; Letizia C; D'Erasmo E; Argenio GF; Salvetti A
Br J Cancer; 2001 Mar; 84(5):636-42. PubMed ID: 11237384
[TBL] [Abstract][Full Text] [Related]
8. Chromogranin A as serum marker of pituitary adenomas.
Gussi IL; Young J; Baudin E; Bidart JM; Chanson P
Clin Endocrinol (Oxf); 2003 Nov; 59(5):644-8. PubMed ID: 14616890
[TBL] [Abstract][Full Text] [Related]
9. Digestive endocrine tumors.
Cadiot G; Baudin E; Partensky C; Ruszniewski P
Gastroenterol Clin Biol; 2006 Sep; 30 Spec No 2():2S91-2S97. PubMed ID: 17151568
[No Abstract] [Full Text] [Related]
10. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role.
Cimitan M; Buonadonna A; Cannizzaro R; Canzonieri V; Borsatti E; Ruffo R; De Apollonia L
Ann Oncol; 2003 Jul; 14(7):1135-41. PubMed ID: 12853358
[TBL] [Abstract][Full Text] [Related]
11. Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas.
Tsao KC; Wu JT
Clin Chim Acta; 2001 Nov; 313(1-2):21-9. PubMed ID: 11694235
[TBL] [Abstract][Full Text] [Related]
12. Hypergastrinemia as a cause of chromogranin a increase in blood in patients suspected to have neuroendocrine tumor.
Kleveland O; Syversen U; Slørdahl K; Waldum HL
Digestion; 2001; 64(2):71-4. PubMed ID: 11684818
[TBL] [Abstract][Full Text] [Related]
13. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1.
Peracchi M; Conte D; Gebbia C; Penati C; Pizzinelli S; Arosio M; Corbetta S; Spada A
Eur J Endocrinol; 2003 Jan; 148(1):39-43. PubMed ID: 12534356
[TBL] [Abstract][Full Text] [Related]
14. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
15. [Usefulness of chromogranin A determination in the diagnosis of neuroendocrine neoplasia].
Militello C; Cannizzaro R; Pradella P; Volpin E; Spirch S; Buonadonna A; De Appollonia L; Rossi C; Sigon R; Cipresso S; Terranova O
Chir Ital; 1999; 51(1):45-51. PubMed ID: 10514916
[TBL] [Abstract][Full Text] [Related]
16. Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report.
Søndenaa K; Sen J; Heinle F; Fjetland L; Gudlaugsson E; Syversen U
World J Surg; 2004 Sep; 28(9):890-5. PubMed ID: 15593463
[TBL] [Abstract][Full Text] [Related]
17. Plasma chromogranin A in incidental non-functioning, benign, solid adrenocortical tumors.
Bernini G; Moretti A; Fontana V; Orlandini C; Miccoli P; Berti P; Basolo F; Faviana P; Bardini M; Salvetti A
Eur J Endocrinol; 2004 Aug; 151(2):215-22. PubMed ID: 15296477
[TBL] [Abstract][Full Text] [Related]
18. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker.
Deftos LJ
Endocr Rev; 1991 May; 12(2):181-7. PubMed ID: 2070778
[TBL] [Abstract][Full Text] [Related]
19. Development of a microplate assay for serum chromogranin A (CgA): establishment of normal reference values and detection of elevated CgA in malignant diseases.
Wu TL; Chang CP; Tsao KC; Sun CF; Wu JT
J Clin Lab Anal; 1999; 13(6):312-9. PubMed ID: 10633301
[TBL] [Abstract][Full Text] [Related]
20. A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A.
Stridsberg M; Eriksson B; Oberg K; Janson ET
Regul Pept; 2004 Mar; 117(3):219-27. PubMed ID: 14749043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]